Item 8.01 Other Events.





On August 7, 2022, CyberOptics Corporation, a Minnesota corporation
("CyberOptics", or the "Company"), Nordson Corporation, an Ohio corporation
("Nordson"), and Meta Merger Company, a Minnesota corporation and a wholly owned
subsidiary of Nordson ("Merger Sub"), entered into an Agreement and Plan of
Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, Merger Sub
will merge with and into CyberOptics, whereupon the separate existence of Merger
Sub will cease, and CyberOptics will be the surviving company as a wholly owned
subsidiary of Nordson (the "Merger").



Under the Merger Agreement, at the effective time of the Merger, each issued and
outstanding share of common stock of the Company (the "Company Common Stock"),
subject to certain exceptions set forth in the Merger Agreement, will be
canceled and extinguished and will be converted into the right to receive $54.00
in cash, without interest (the "Merger Consideration").



Following the filing of CyberOptics' preliminary proxy statement associated with
the Merger with the SEC on September 12, 2022, Shiva Stein filed a complaint
captioned Stein v. CyberOptics Corporation, et al., Case No. 1:22-cv-7823, in
the United States District Court for the Southern District of New York (the
"Stein Complaint"). The Stein Complaint generally alleges that CyberOptics'
preliminary proxy statement omits material information with respect to the
Merger and that, as a result, CyberOptics and each member of the CyberOptics'
Board of Directors (the "CyberOptics Board") violated Section 14(a) of the
Securities Exchange Act of 1934 (the "Exchange Act") and that each CyberOptics
Board member violated Section 20(a) of the Exchange Act. The Stein Complaint
also alleges that all defendants also violated 17 C.F.R. § 244.100. The
Complaint seeks (i) injunctive relief; (ii) rescission in the event the Merger
is consummated or alternatively rescissory damages; (iii) granting an accounting
for all damages suffered, (iv) plaintiff's attorneys' and experts' fees and
costs; and (v) other such relief that the court deems just and proper. On
October 13, 2022, Christopher Taylor filed a complaint captioned Taylor v.
CyberOptics Corporation et al., Case No. 1:22-cv-08727, in the United States
District Court for the Southern District of New York (the "Taylor Complaint").
The Taylor Complaint makes similar allegations and seeks similar relief as the
Stein Complaint. In addition, counsel for seven shareholders delivered demand
letters to the CyberOptics, which threatened the filing of similar lawsuits.



On September 26, 2022, CyberOptics filed the definitive merger proxy statement (the "Proxy Statement").

CyberOptics and the individual defendants believe that CyberOptics has
previously disclosed all information required to be disclosed to ensure that its
shareholders can make an informed vote at the Special Meeting (as defined below)
and that the additional disclosures requested by the plaintiffs are not required
by the federal securities laws or Minnesota law, and are otherwise immaterial.
Accordingly, CyberOptics and the individual defendants believe the claims
asserted in the Merger Complaints are without merit. However, in order to reduce
the costs, risks and uncertainties inherent in litigation, CyberOptics has
determined voluntarily to supplement the Proxy Statement as described in this
Current Report on Form 8-K (the "Report"). Nothing in this Report shall be
deemed an admission of the legal necessity or materiality under applicable laws
of any of the disclosures set forth herein. To the contrary, CyberOptics and the
CyberOptics board of directors specifically deny all allegations in the Merger
Complaints that any additional disclosure was or is required.


The CyberOptics' Board recommends that you vote: (1) "FOR" the adoption of the
merger agreement; (2) "FOR" the compensation that will or may become payable by
CyberOptics to its named executive officers in connection with the merger; and
(3) "FOR" the adjournment of the special meeting, from time to time, to a later
date or dates, if necessary or appropriate as determined in good faith by
CyberOptics' Board of Directors, to solicit additional proxies if there are
insufficient votes to adopt the merger agreement at the time of the special
meeting.



These supplemental disclosures will not affect the merger consideration or the
timing of CyberOptics' Special Meeting of Shareholders scheduled for November 2,
2022, at 10:00 a.m. Central time (the "Special Meeting"), which will be held at
CyberOptics headquarters located at 5900 Golden Hills Drive, Minneapolis, MN
55416.


If you have any questions or need assistance voting your shares, please contact CyberOptics' proxy solicitor:

Okapi Partners
                    1212 Avenue of the Americas, 24th Floor
                               New York, NY 10036
                  Shareholders call toll-free: (877) 274-8654
                 Banks and brokers call collect: (212) 297-0720








Supplemental Disclosures to Proxy Statement


This supplemental information should be read in conjunction with the Proxy
Statement, which should be read in its entirety. Defined terms used but not
defined below have the meanings set forth in the Proxy Statement. All page
references in the information below are to pages in the Proxy Statement.
Paragraph references used herein refer to the Proxy Statement before any
additions or deletions resulting from the supplemental disclosures. Where
appropriate, bolded text shows text being added to a referenced disclosure in
the Proxy Statement and strikethrough text shows text being removed from the
Proxy Statement. The information contained herein speaks only as of October 21,
2022 unless the information indicates another date applies.



1. The disclosure under the heading "The Merger-Unaudited Prospective Financial

Information-Financial Information" on page 37, is deleted in its entirety and


    replaced with the following:




Financial Forecasts



The following table sets forth figures contained in the Financial Forecast, as
shared with the CyberOptics Board and as approved by CyberOptics management to
be shared with potential bidders:



                                             Year ending December 31,
$ in millions except per share amounts     2022         2023        2024
Revenue                                  $   106.9     $ 123.0     $ 142.0
Cost of goods                                 57.1        65.7        75.8
Gross margin                                  49.9        57.3        66.2
Research & development                        12.3        12.9        13.8
Sales and marketing                           12.2        13.6        15.2
General and administrative                     7.5         7.7         8.2

Total Direct Operating Expenses               32.0        34.2        37.2

Operating income                              17.8        23.1        29.0
Interest and other                             0.3         0.5         0.8
Pre-tax income                                18.2        23.6        29.8
Taxes                                          2.2         3.3         4.8
Net income                               $    16.0     $  20.3     $  25.0
EPS                                      $    2.10     $  2.67     $  3.29

2. The disclosure under the heading "The Merger-Unaudited Prospective Financial

Information-Additional Financial Information" on page 37 is hereby amended to


    add the following new paragraph below the table:




The following table sets forth prospective unlevered free cash flows for the
periods indicated:



                                    Stub Period
                                       Ending                Year ending
                                    December 31,            December 31,             Terminal
$ in millions                         2022(2)            2023           2024           Year

Unlevered free cash flows (1) $ 6.7 $ 15.0 $ 19.4 $ 22.6

(1) "Unlevered" free cash flows are a non-GAAP measure calculated as adjusted


     operating income plus depreciation and amortization, and less capital
     expenditures, changes in net working capital and taxes.


(2) Represents the period from August 5, 2022 to December 31, 2022.

3. The first paragraph under the heading "The Merger-Unaudited Prospective

Financial Information-Additional Financial Information" that begins under the


    table on page 37 is amended as follows:




Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income, and
Adjusted earnings per share and unlevered free cash flows are non-GAAP financial
measures within the meaning of the applicable rules and regulations of the SEC,
which are financial measures that are not calculated in accordance with GAAP.
Non-GAAP financial measures should not be viewed as a substitute for GAAP
financial measures and may be different from non- GAAP financial measures used
by other companies. Accordingly, non-GAAP financial measures should be
considered together with, and not as an alternative to, financial measures
prepared in accordance with GAAP. SEC rules that may otherwise require a
reconciliation of a non-GAAP financial measure to a GAAP financial measure do
not apply to non-GAAP financial measures provided to directors or a financial
advisor (like the Additional Financial Information) in connection with a
proposed transaction like the merger when the disclosure is included in a
document like this proxy statement. In addition, reconciliations of non- GAAP
financial measures to GAAP financial measures were not relied upon by Barclays
for purposes of its opinion or by the CyberOptics Board in connection with its
consideration of the merger. Accordingly, CyberOptics has not provided a
reconciliation of the EBITDA to the relevant GAAP financial measures.



4. The disclosure under the heading "The Merger-Opinion of Barclays Capital,

Inc.-Summary of Material Financial Analyses-Selected Comparable Company

Analysis" is hereby amended by deleting the first two tables on page 46 of the


    Proxy Statement and replacing them with the following two tables:




EV as a Multiple of EBITDA



                               2022E           2023E
Small Cap.
Nova Ltd.                      15.8x           15.9x
Onto Innovation Inc.           13.2x           11.8x
Camtek Ltd.                    11.7x           11.5x
Mycronic AB                    12.6x           12.2x
FormFactor, Inc.               15.0x           12.2x
Small Cap. Median              13.2x           12.2x
Large Cap.
KLA Corporation                13.8x           13.9x
Lam Research Corporation       12.3x           12.2x
Applied Materials, Inc.        11.8x           11.3x
Teradyne, Inc.                 16.5x           14.5x
Large Cap Median               13.1x           13.0x
Overall Median                 13.2x           12.2x
Range                      11.7x - 16.5x   11.3x - 15.9x




P/E



                               2022E           2023E
Small Cap.
Nova Ltd.                      22.1x           21.8x
Onto Innovation Inc.           17.3x           16.0x
Camtek Ltd.                    16.8x           16.7x
Mycronic AB                    20.1x           19.3x
FormFactor, Inc.               23.7x           19.5x
Small Cap Median               20.1x           19.3x
Large Cap.
KLA Corporation                17.3x           16.5x
Lam Research Corporation       14.7x           14.1x
Applied Materials, Inc.        14.4x           13.2x
Teradyne, Inc.                 25.5x           20.2x
Large Cap Median               16.0x           15.3x
Overall Median                 17.3x           16.7x

Range                      14.4x - 25.5x   13.2x - 21.8x









5. The disclosure under the heading "The Merger-Opinion of Barclays Capital,

Inc.-Summary of Material Financial Analyses-Selected Precedent Transaction

Analysis" is hereby amended by deleting the first table on page 47 of the


    Proxy Statement and replacing it with the following table:




   Date                                          Enterprise Value      EV/Revenue        EV/EBITDA
Announced       Acquiror          Target              ($mm)               FTM         LTM        FTM
                              CMC Materials,
12/15/2021   Entegris, Inc.   Inc.              $            6,475       5.16x       18.1x      17.6x
             EnPro
             Industries,
11/5/2021    Inc.             NxEdge, Inc.                     850        N/A        12.1x       N/A
             MKS
             Instruments,
 7/1/2021    Inc.             Atotech Ltd.                   6,500       4.74x       19.3x      14.0x
             MKS
             Instruments,     Photon Control,
5/10/2021    Inc.             Inc.                             283       4.50x       16.5x      15.2x
3/25/2021    II-VI, Inc.      Coherent, Inc.                 6,961       4.77x       44.9x      25.9x
                              Ham-Let
             Ultra Clean      (Israel-Canada)
12/16/2020   Holdings, Inc.   Ltd.                             348        N/A        14.5x       N/A
                              Rudolph
             Nanometrics,     Technologies,
6/24/2019    Inc.             Inc.                             698       2.59x       12.9x      13.7x
                              Electro
             MKS              Scientific
             Instruments,     Industries,
10/30/2018   Inc.             Inc.                             911       2.87x        6.6x      10.6x
             KLA-Tencor
3/19/2018    Corp.            Orbotech Ltd.                  3,184       3.13x       16.7x      14.0x
             Kohlberg
             Kravis Roberts   Hitachi Kokusai
4/26/2017    & Co. LP         Electric, Inc.                 2,427       1.42x       15.2x      10.3x
             Veeco
             Instruments,
 2/2/2017    Inc.             Ultratech, Inc.                  541       2.53x       18.6x      16.5x
                              Hermes
             ASML Holding     Microvision,
6/15/2016    NV               Inc.                           2,847       9.33x       39.5x      22.2x
                              Rofin-Sinar
                              Technologies,
3/16/2016    Coherent, Inc.   Inc.                             802       1.56x       10.3x      10.4x
             MKS
             Instruments,
. . .

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits




Exhibit
No.     Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses